EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SARS-CoV-2 Vaccine Immunogenicity in Patients with Gastrointestinal Cancer Receiving Systemic Anti-Cancer Therapy

David K Lau, Maria Aresu, Timothy Planche, Amina Tran, Retchel Lazaro-Alcausi, Julie Duncan, Shannon Kidd, Susan Cromarty, Ruwaida Begum, Isma Rana, Su Li, Ali Abdulnabi Suwaidan und 14 weitere

The Oncologist · 2023

DOI: 10.1093/oncolo/oyac230 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2023. Verfasst von David K Lau und 25 weiteren Autor:innen. Beteiligte Einrichtung: Gastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation Trust, London and Surrey, UK. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, Gastrointestinal Neoplasms, Immunogenicity, Vaccine. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Royal Marsden Cancer Charity, Rosetrees Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Patients with gastrointestinal (GI) cancers have an increased risk of serious complications and death from SARS-CoV-2 infection. The immunogenicity of vaccines in patients with GI cancers receiving anti-cancer therapies is unclear. We conducted a prospective study to evaluate the prevalence of neutralizing antibodies in a cohort of GI cancer patients receiving chemotherapy following SARS-CoV-2 vaccination. Materials and Methods Between September 2020 and April 2021, patients with cancer undergoing chemotherapy were enrolled. At baseline (day 0), days 28, 56, and 84, we assessed serum antibodies to SARS-CoV-2 spike (anti-S) and anti-nucleocapsid (anti-NP) and concomitantly assessed virus neutralization using a pseudovirus neutralization assay. Patients received either the Pfizer/BioNTech BNT162b2, or the Oxford/AstraZeneca ChAdOx1 vaccine.

Results

All 152 patients enrolled had a prior diagnosis of cancer; colorectal (n = 80, 52.6%), oesophagogastric (n = 38, 25.0%), and hepato pancreatic biliary (n = 22, 12.5%). Nearly all were receiving systemic anti-cancer therapy (99.3%). Of the 51 patients who did not receive a vaccination prior to, or during the study, 5 patients had detectable anti-NP antibodies. Ninety-nine patients received at least one dose of vaccine prior to, or during the study. Within 19 days following the first dose of vaccine, 30.0% had anti-S detected in serum which increased to 70.2% at days 20-39. In the 19 days following a second dose, anti-S positivity was 84.2% (32/38). However, pseudovirus neutralization titers (pVNT80) decreased from days 20 to 39.

Conclusion

Despite the immunosuppressive effects of chemotherapy, 2 doses of SARS-CoV-2 vaccines are able to elicit a protective immune response in patients’ ongoing treatment for gastrointestinal cancers. Decreases in pseudoviral neutralization were observed after 20-39 days, re-affirming the current recommendation for vaccine booster doses. Clinical Trial Registration Number NCT04427280.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19COVID-19 VaccinesGastrointestinal NeoplasmsImmunogenicity, VaccineHumansAntibodiesBNT162 VaccineProspective StudiesSARS-CoV-2

Stichwörter der Autor:innen

COVID-19SARS-CoV-2anti-spikechemotherapygastrointestinal cancerimmunitypseudovirusvaccines

Substanzen

AntibodiesBNT162 VaccineCOVID-19 Vaccines

Autor:innen und Institutionen

  • Gastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation Trust, London and Surrey, UK.
  • Department of Clinical Research and Development, Royal Marsden NHS Foundation Trust, London and Surrey, UK.
  • Centre for Diagnostics & Antimicrobial Resistance, Clinical Academic Group in Institute for Infection & Immunity, St George's University of London, London, UK.
  • St George's University Hospitals NHS Foundation Trust, London, UK.
  • Institut für Tropenmedizin, Universitätsklinikum Tübingen, Tübingen, Germany.
  • Centre de Recherches Médicales de Lambaréné, Gabon, Lambaréné.

ORCID-Profile: Nigel Temperton, Naureen Starling, Ian Chau

Förderung

  • Wellcome Trust
  • Royal Marsden Cancer Charity
  • Rosetrees Trust
  • John Black Charitable Foundation

Zitieren

APA

Lau, D. K., Aresu, M., Planche, T., Tran, A., Lazaro-Alcausi, R., Duncan, J., Kidd, S., Cromarty, S., Begum, R., Rana, I., Li, S., Suwaidan, A. A., Monahan, I., Clark, D. J., Eckersley, N., Staines, H. M., Groppelli, E., Krishna, S., Mayora-Neto, M., …, & Rao, S. (2023). SARS-CoV-2 Vaccine Immunogenicity in Patients with Gastrointestinal Cancer Receiving Systemic Anti-Cancer Therapy. The Oncologist. https://doi.org/10.1093/oncolo/oyac230

Vancouver

Lau DK, Aresu M, Planche T, Tran A, Lazaro-Alcausi R, Duncan J, et al. SARS-CoV-2 Vaccine Immunogenicity in Patients with Gastrointestinal Cancer Receiving Systemic Anti-Cancer Therapy. The Oncologist. 2023. doi:10.1093/oncolo/oyac230

BibTeX
@article{Lau2023,
  author = {Lau, David K and Aresu, Maria and Planche, Timothy and Tran, Amina and Lazaro-Alcausi, Retchel and Duncan, Julie and Kidd, Shannon and Cromarty, Susan and Begum, Ruwaida and Rana, Isma and Li, Su and Suwaidan, Ali Abdulnabi and Monahan, Irene and Clark, David J and Eckersley, Nicholas and Staines, Henry M and Groppelli, Elisabetta and Krishna, Sanjeev and Mayora-Neto, Martin and Temperton, Nigel and Fribbens, Charlotte and Watkins, David and Starling, Naureen and Chau, Ian and Cunningham, David and Rao, Sheela},
  title = {SARS-CoV-2 Vaccine Immunogenicity in Patients with Gastrointestinal Cancer Receiving Systemic Anti-Cancer Therapy},
  journal = {The Oncologist},
  year = {2023},
  doi = {10.1093/oncolo/oyac230}
}
Kostenlos starten →